| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT05550519 2021-005588-39 Details | 2022-10-31 Interventional | 1 | 0 | Entecavir Tenofovir Hepatitis Hepatitis A Hepatitis B Hepatitis B, Ch… | Sponsor decision after reevaluation of strategy in the context of recruitment timelines
projection - | |||
| NCT04684394 Details | 2022-10-31 Interventional | 2 | 50 | Aflibercept Macular Degener… Retinal Degener… Retinal Disease… Wet Macular Deg… Neovascular Age… Retinal Disease | Sponsor decision - | |||
| NCT04429880 Details | 2022-10-31 Interventional | 2 | 0 | Oxytocin Osteoarthritis,… | Study was not initiated; no subjects enrolled. A replacement study will be submitted - | |||
| NCT03579472 Details | 2022-10-31 Interventional | 1 | 38 | Halichondrin B Breast Neoplasm… Triple Negative… Anatomic Stage … Metastatic Trip… Prognostic Stag… | Due to the fact that the sponsor decided not to move forward with the development of M7824 - | |||
| NCT03472872 Details | 2022-10-31 Interventional | 4 | 500 | Acetaminophen Ketorolac Emergencies Headache | no longer recruiting or studying - | |||
| NCT02598778 Details | 2022-10-31 Interventional | 2 | 12 | Chlorhexidine Chlorhexidine g… Fluorides Listerine Sodium Fluoride Dental Caries | Study discontinued early due to time constraints and lack of selectivity in agar used in the
identification of the target (Streptococcus mutans). Only 12 participants out of a planned 40
were enrolled. - | |||
| NCT04441398 Details | 2022-10-28 Interventional | 2/3 | 0 | Nitazoxanide COVID-19 covid19 | Sponsor's strategic decision - | |||
| NCT04435314 Details | 2022-10-28 Interventional | 2 | 0 | Nitazoxanide COVID-19 covid19 | Sponsor's strategic decision - | |||
| NCT03521934 2017-003510-16 Details | 2022-10-28 Interventional | 3 | 1222 | (2S,3R,4R,5S,6R… Diabetes Mellit… Diabetes Mellit… Heart Failure Type 2 Diabetes… | Study terminated due to business decision Limitations of the trial such as small numbers of participants analyzed or technical problems leading to unreliable data. The study was terminated prematurely due to business decision. | |||
| NCT03315143 2017-002644-32 Details | 2022-10-28 Interventional | 3 | 10584 | (2S,3R,4R,5S,6R… Diabetes Mellit… Diabetes Mellit… Kidney Diseases Renal Insuffici… Chronic Kidney … Heart Failure Type 2 Diabetes… | study terminated due to business decision The study was terminated prematurely due to business decision. | |||
| NCT02811783 Details | 2022-10-28 Interventional | 3 | 59 | Naloxone Lymphoma Lymphoma, T-Cel… Lymphoma, T-Cel… Mycoses Mycosis Fungoid… Pruritus Sezary Syndrome Sézary Syndrom… | Sponsor decision - | |||
| NCT05433402 Details | 2022-10-27 Interventional | 1/2 | 0 | Chlorpromazine Colonic Neoplas… Colon Cancer St… | Organizational safety isues - | |||
| NCT05209165 Details | 2022-10-27 Interventional | 4 | - | Semaglutide Atrial Fibrilla… Overweight Obesity | Company decision - | |||
| NCT03578198 Details | 2022-10-27 Interventional | 2 | 12 | Rituximab Lymphoma Lymphoma, Non-H… CD20-positive N… | Issues in supply of IP - | |||
| NCT03119038 Details | 2022-10-27 Interventional | 4 | 0 | Bupivacaine Clonidine Epinephrine Ketorolac Ropivacaine Joint Diseases Osteoarthritis Pain, Postopera… Degenerative Jo… | Investigator no longer actively pursuing this study. - | |||
| NCT03099265 Details | 2022-10-27 Interventional | 2 | 9 | Fluorouracil Irinotecan Leucovorin Oxaliplatin Adenocarcinoma Pancreatic Canc… | Paused due to COVID. A determination was made to stop the study because it would be impossible
to reach the 65% resection rate as outlined in the protocol. - | |||
| NCT02812862 Details | 2022-10-27 Interventional | 4 | 0 | Olodaterol Tiotropium Brom… Heart Failure COPD | Rationale obsolete - | |||
| NCT05066698 Details | 2022-10-25 Interventional | 2 | 8 | Ophthalmic Solu… Persistent Corn… | Sponsor undergoing financial hardships - no longer able to support trial; no safety concerns. - | |||
| NCT04780061 Details | 2022-10-25 Interventional | 3 | 90 | Cholecalciferol Vitamin D Vitamin K Vitamin K 2 Vitamins COVID-19 Covid19 | Public PCR testing stopped in Ontario - | |||
| NCT04460430 2019-000710-11 Details | 2022-10-25 Interventional | 2 | 12 | Neratinib Breast Neoplasm… Breast Cancer | premature termination due to lack of funding - |